Literature DB >> 7930698

Frequent reinfection and reactivation of hepatitis C virus genotypes in multitransfused hemophiliacs.

L M Jarvis1, H G Watson, F McOmish, J F Peutherer, C A Ludlam, P Simmonds.   

Abstract

The frequency and dynamics of infection with different genotypes of hepatitis C virus were investigated in a cohort of hemophiliacs repeatedly exposed to non-virus-inactivated clotting factor. Among 63 infected hemophiliacs, genotype 1 (n = 38, subtypes 1a [27] and 1b [11]) was predominant; genotypes 2a (n = 1), 2b (n = 3), 3a (n = 20), and 5a (n = 1) accounted for the remainder. This distribution was similar to that found in Scottish blood donors from whom the infected blood products were manufactured. Hemophiliacs with severe disease were more likely to be polymerase chain reaction-positive than those with moderate or mild disease. Over 10 years, changes in the circulating major genotype and serotype were observed in 9 of 29 hemophiliacs and from one subtype to another in 3, although there was no clear trend toward replacement with any particular variant. Replacement occurred after the introduction of inactivated clotting factor in 4 subjects, implicating reactivation rather than reinfection. Those coinfected with human immunodeficiency virus were more likely to show a change in genotype.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7930698     DOI: 10.1093/infdis/170.4.1018

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  20 in total

1.  Interferon-alpha for reinfection with hepatitis C virus in two patients with chronic hepatitis C who had responded to previous therapies.

Authors:  Norio Akuta; Fumitaka Suzuki; Akihito Tsubota; Yoshiyuki Suzuki; Takashi Someya; Masahiro Kobayashi; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Yuzo Miyakawa; Hiromitsu Kumada
Journal:  Dig Dis Sci       Date:  2003-08       Impact factor: 3.199

2.  Molecular epidemiology of hepatitis C among drug users in Flanders, Belgium: association of genotype with clinical parameters and with sex- and drug-related risk behaviours.

Authors:  C Matheï; E Wollants; J Verbeeck; M Van Ranst; G Robaeys; P Van Damme; F Buntinx
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-08       Impact factor: 3.267

3.  HCV genotype 2 as a risk factor for reactivation of chronic HCV infection.

Authors:  N Coppola; L M Vatiero; E Sagnelli
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

4.  HCV transmission in family members of subjects with HCV related chronic liver disease.

Authors:  L Demelia; E Vallebona; R Poma; G Sanna; G Masia; R C Coppola
Journal:  Eur J Epidemiol       Date:  1996-02       Impact factor: 8.082

5.  Long-term evolution of the hypervariable region of hepatitis C virus in a common-source-infected cohort.

Authors:  J McAllister; C Casino; F Davidson; J Power; E Lawlor; P L Yap; P Simmonds; D B Smith
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

6.  Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode.

Authors:  I Nakano; G Maertens; M E Major; L Vitvitski; J Dubuisson; A Fournillier; G De Martynoff; C Trepo; G Inchauspe
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

Review 7.  Hepatitis C virus: molecular biology and genetic variability.

Authors:  C Bréchot
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

Review 8.  Mixed HCV infection and reinfection in people who inject drugs--impact on therapy.

Authors:  Evan B Cunningham; Tanya L Applegate; Andrew R Lloyd; Gregory J Dore; Jason Grebely
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-03-17       Impact factor: 46.802

9.  Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colony-stimulating factor gene.

Authors:  S W Lee; J H Cho; Y C Sung
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

10.  Clinical significance of intrahepatic hepatitis C virus levels in patients with chronic HCV infection.

Authors:  G H Haydon; L M Jarvis; C S Blair; P Simmonds; D J Harrison; K J Simpson; P C Hayes
Journal:  Gut       Date:  1998-04       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.